Skip to Content

Deferiprone Dosage

The information at is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Iron Overload

Iron overload due to thalassemia: The recommended initial dose is 25 mg/kg, orally, three times daily for a total of 75 mg/kg/day.

Renal Dose Adjustments

Data not available.

Liver Dose Adjustments

Data not available.

Dose Adjustments

Dose adjustments up to 33 mg/kg, orally, three times per day should be tailored to the individual patient's response and therapeutic goals (maintenance or reduction of body iron burden). The maximum recommended total daily dose is 99 mg/kg per day. The dose should be rounded by the prescriber to the nearest 250 mg (half-tablet).

No dosage adjustment is recommended based on gender, weight, ethnicity, or geriatric status.


Measure the absolute neutrophil count (ANC) before starting deferiprone and monitor the ANC weekly on therapy. Interrupt deferiprone if infection develops and monitor the ANC more frequently. Advise patients taking deferiprone to report immediately any symptoms indicative of infection and immediately interrupt deferipone therapy. If neutropenia develops (ANC less than 1.5 x 10(9)/L), interrupt deferiprone therapy.

If ANC is less than 1.5 x 10(9)/L but greater than 0.5 x 10(9)/L), instruct the patient to immediately discontinue deferiprone and all other medications with a potential to cause neutropenia. Obtain a complete blood cell (CBC) count, including a white blood cell (WBC) count corrected for the presence of nucleated red blood cells, an absolute neutrophil count (ANC), and a platelet count daily until recovery (ANC greater than or equal to 1.5 x 10(9)/L).
If ANC is less than 0.5 x 10(9)/L), consider hospitalization and other management as clinically appropriate. Do not resume deferiprone in patients who have developed agranulocytosis unless potential benefits outweigh potential risks. Do not rechallenge patients who develop neutropenia with deferiprone unless potential benefits outweigh potential risks.

Monthly monitoring of serum ALT values is recommended during therapy with deferiprone. Consider interruption of therapy if there is a persistent increase in the serum transaminase levels.

Plasma zinc level monitoring is recommended along with zinc supplementation in the event of a deficiency.

Safety and effectiveness in elderly individuals have not been established. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Data not available.